🔴 We are now live with an insightful presentation by Dr. Jürgen Scheuenpflug, PhD, Executive Director and Head of Strategic Innovation at Merck Healthcare, Germany, sharing an industry perspective on the evolving landscape of liquid biopsy.
Presentation: LBx Industry Perspective: Clinical Utility, Challenges, Emerging Opportunities
In this session, Dr. Scheuenpflug is exploring how liquid biopsy is transitioning from a promising research technology to an increasingly valuable tool in routine clinical practice. Drawing on his extensive experience in healthcare innovation and precision medicine, he discusses the opportunities and challenges involved in bringing liquid biopsy solutions from the laboratory to patients.
The presentation highlights key topics including clinical utility, regulatory pathways, reimbursement, healthcare system integration, and technology adoption, while examining how collaboration between academia, industry, clinicians, and regulators can accelerate the implementation of liquid biopsy across cancer care.
Dr. Scheuenpflug also shares valuable insights into the future of precision oncology, emphasizing the importance of innovation, evidence generation, and strategic partnerships in advancing minimally invasive diagnostics and improving patient outcomes worldwide.
This engaging session provides attendees with a comprehensive industry perspective on the next phase of liquid biopsy development and its growing impact on personalized cancer medicine.
We extend our sincere thanks to Dr. Jürgen Scheuenpflug for sharing his expertise and to our global audience for participating in this important scientific discussion.
This conference is organized by Impact Research Communications (IRC)
More info: https://liquidbio.ircconferences.net/ | Advances in Liquid Biopsy
